Have you used any approaches involving genome-wide association analyses, transcriptome analyses, proteome protein expression profiling and in vivo and in vitro functional analyses of specific genes of interest and the like? If so, this please select this category.
Have you elucidated any functional changes related to osteoporosis, or found novel molecular targets? If so, please select this category.
Does your presentation address the biology dealing with immunologic effects on such phenomena as infectious disease, growth and development, recognition phenomena, hypersensitivity, heredity, aging, transplantation. If so, please select this category.
Have you developed any commercial or professional procedures that are accepted or prescribed as being correct or highly effective in treating osteoporosis. If so, please select this category.
Is your abstract related to the importance of nutrition and dietary needs of patients with osteoporosis? Are you sharing information on safe movements and exercise for patients? If so, please select this category.
Does your abstract address how to communicate with patients about sexuality and safety during sexual activities? If so, please select this category.
If your abstract is related to Fracture Liaison Services, please select this category.
If your abstract is related to Paget’s Disease in any way please select this category.
If your abstract reflects the implementation of novel therapies for the treatment of osteoporosis, please select this category.
If your abstract falls outside of the other categories, please select this category .
After the submission deadline, all completed and eligible abstracts will be made available to the NOF Abstract Reviewers for blinded review and scoring, and final decisions will be made by the Program Committee in late January 2018.
Abstracts will be evaluated and scored solely on their scientific merits. Incomplete abstracts will not be reviewed. The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected. Abstracts will be peer reviewed according to the subject categories. Authors must indicate during online submission the appropriate review category (one only). Please use the list of abstract review categories. Read through all of the categories and select the category most closely associated with your abstract. All category selections will be final. There will be NO re-classification of abstracts after the abstract submission site has been closed. Abstracts submitted to the wrong category are scored in that category and usually fare poorly.
All abstracts submitted will be considered eligible for one presentation: either plenary, oral (simultaneous session), or poster.
The Plenary Session features the top abstracts. These are formal oral presentations, each followed by a brief discussion. An NOF member selected by the Program Committee will give a brief introduction to the abstract.
Oral (simultaneous) Sessions are formal oral presentations followed by a brief discussion.
Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. The author’s attendance during poster presentation time will be monitored.
Notification regarding acceptance or rejection of abstracts will be sent to the presenting author in January 2018 by email; consequently, an accurate email address is critical. If your abstract is accepted, the email will specify whether it is accepted as plenary, oral, or poster presentation or whether it has been selected to be published online only. If you have not received an email notification by February 2, 2018, contact Catrell Harris at catrell.harris@nof.org. Rejection notifications will also be sent at that time.
The decision of the NOF Program Committee regarding acceptance and presentation of abstracts is final.
The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system. The presenting author must be one of the co-authors listed on the submitted abstract.
The presenting author is responsible for the following: Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract. Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by NOF. Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors. Forwarding all correspondence to all co-authors, including NOF policies and guidelines and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME).
Each abstract author agrees and certifies that he or she: